Verona Pharma (VRP)

 

VRP Share PerformanceMore

52 week high210.00 24/10/16
52 week low105.10 28/06/17
52 week change -29.00 (-19.02%)
4 week volume921,338 25/07/17

Media for (VRP)

Presenter: Jan-Anders Karlsson
28/07/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Verona Pharma losses widen as it starts clinical trials

Verona Pharma (VRP), a clinical-stage biopharmaceutical company, made a loss after tax of 5.1 million in the first half, co...

Verona Pharma plc Interim Results for the Six Months Ended June 30, 2017 and Clinical Development Update

Verona Pharma plc Interim Results for the Six Months Ended June 30, 2017 and Clinical Development Update Completed US IPO Continues to advance lead candidate RPL554 with four clinical trials commenced LONDON, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-sta...

Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development Update

Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development Update LONDON, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for resp...

Verona to present at healthcare conference

Verona Pharma has confirmed that Jan-Anders Karlsson, PhD, CEO of the Company, is scheduled to present at the 2017 W...

Verona Pharma to Present at 2017 Wedbush PacGrow Healthcare Conference

Verona Pharma to Present at 2017 Wedbush PacGrow Healthcare Conference LONDON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Jan-Ande...

Verona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment

Verona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment Dose escalation trial will evaluate RPL554 in approximately 400 COPD patients LONDON, July 26, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on...

Verona nears Phase 2b clinical trial for RPL554

Verona Pharma announces regulatory approval in five European countries for a Phase 2b dose-ranging trial of RPL554 fo...

Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across Europe

Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across Europe Dose escalation trial will evaluate RPL554 as a maintenance treatment in approximately 400 COPD patients LONDON, June 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:V...

Fundamental DataMore

EPS-0.74
Dividend yield0 %

Equity Research (VRP)

edison investment research
Verona Pharma plc
26/07/2016
Verona’s £44.7m gross raise removes funding uncertainty, allowing the company to focus on the clinical progress of its respiratory asset RPL554, a dual PDE3/PDE4 inhibitor. RPL554 is in development...
hardman & co
Verona Pharma plc
20/06/2016
VRP is developing first-in-class drugs to treat unmet medical needs in respiratory disease. Over the last two years’ VRP has reported positive outcomes from a five stage Phase I/IIa programme which...
hardman & co
Verona Pharma plc
16/03/2016
VRP is developing first-in-class drugs that treat unmet medical needs in respiratory disease. RPL554 is being fast-tracked to commercialisation by focusing on a $3.2bn market segment poorly serviced...

Latest discussion posts More

  • Latest Corporate Presentation

    slides available - presumably used in wedbush presentation ...
    16-Aug-2017
    mol42
  • Re: Directors Pay

    Taken years already and if they want that sort of pay it wont belong before you can divide the share price by 10 again..
    19-Jun-2017
    Philbot44
  • Re: Directors Pay

    Hi Raptor & MOL, Full credit to you guys for 'Holding On' in VRP, (Rap I guess you meant email VRP not N?). I held these shares for about a year and sold out when VRP ...
    19-Jun-2017
    lawrence77

Users' HoldingsMore

Users who hold Verona Pharma also hold..
LLOYDS GRP.20%
RENEURON11%
GULF KEYSTONE11%
BP10%
RANGE RES.10%

Codes & Symbols

ISINGB00BYW2KH80
SymbolsVRP, LSE:VRP, VRP.L, VRP:LN, LON:VRP, XLON:VRP